2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2985

Practice-Level Variation in Quality of Care in the Acr’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 2986

Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Abstract Number: 2987

Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Abstract Number: 2988

Cigarette Smoking Increases the Risk of Anti-Double-Stranded DNA Positive SLE Among Women in the Nurses’ Health Studies
Abstract Number: 2989

Risk of Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort
Abstract Number: 2990

Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort
Abstract Number: 2991

A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population
Abstract Number: 2992

In Systemic Lupus Erythematosus with Antiphospholipid Antibodies, Hypocomplementemia Associates with Thrombosis
Abstract Number: 2993

Membrane-Type 1 Matrix Metalloproteinase Controls Osteo- and Chondrogenesis By a Proteolysis-Independent Mechanism Mediated By Its Cytoplasmic Tail
Abstract Number: 2994

Binding of Periostin to Discoidin Domain Receptor-1 (DDR1) Promotes Cartilage Degeneration By Inducing MMP-13 Expression
Abstract Number: 2995

WISP1/CCN4 Aggravates Experimental Osteoarthritis and Is Associated with Disease Progression in Early Osteoarthritis Patients
Abstract Number: 2996

High Fat Diet-Induced Osteoarthritis Progression Is Dependent on Toll-like Receptor 4
Abstract Number: 2997

Microrna-29a Curtails Synovitis in the Development of Knee Osteoarthritis By Disrupting VEGF
Abstract Number: 2998

Gut Microbiota Induce IGF-1 and Promote Bone Formation and Growth
Abstract Number: 2999

Autologous Osteoblastic Cells Versus Concentrated Bone Marrow Implantation in Osteonecrosis of the Femoral Head: A Randomized Controlled Single Blind Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].